Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Table 3 Factors associated with progression-free survival in patients with brain metastases.

Factor	Median (months)	CI (95%)	Univariate analysis	RR	CI (95%)	Multivariate analysis
			P ^§			P^§
Gender
Male	NA	(11.3-22.9)	0.257
Female	19.6
Age (years)
<55	13.9	(8.8-19.1)	<0.001	0.22	(0.046 - 1.07)	0.06
≥55	NA
KPS
<80	28.1	(13.9 - 42)	0.946
≥80	22.3	(12.3-32.3)
Number of metastases
<4	22.3	(11.3 - 33.2)	0.351
≥4	14.9	(1.9 - 27.9)
Histology
NSCLC and others	NA	(6.6 -11.0)	<0.001	0.46	(0.13 – 1.7)	0.24
Breast cancer	8.8
Time of brain metastasis
During primary tumor diagnosis	22.3	(5.5 - 39)	0.089
During recurrence	19.6	(10.1 - 29)
Treatment
Control arm	13.2	(6.3 - 20.1)	0.001	0.31	(0.1 – 0.9)	0.046
CLQ arm	NA

Abbreviations: SE standard error, KPS Karnofsky performance status, NSCLC non-small-cell lung cancer, CHT chemotherapy, CLQ chloroquine. ^§P log-rank test.

ISSN: 1748-717X